Schrodinger, Inc. (SDGR) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Schrodinger, Inc.'s filing signal turned positive.

Schrödinger, Inc. is a computational chemistry company that develops physics-based software for drug discovery and materials science applications. Its platform enables the rapid and cost-effective identification and design of novel molecules, serving biopharmaceutical companies, academic institutions, and government laboratories globally. In 2025, all of the top 20 pharmaceutical companies licensed Schrödinger's solutions, contributing 37% of its software revenue. The company also leverages its platform for a pipeline of proprietary drug discovery programs, advancing candidates like SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor) through clinical trials. Schrödinger's business model combines software licensing with revenue generated from collaborative drug discovery programs, including upfront payments, milestone payments, and royalties.

Revenue is driven by software licensing, subscriptions, maintenance, and professional services for its computational platform. Additionally, drug discovery revenue is generated through collaboration agreements, including upfront payments, milestone payments, and royalties from successful drug development.